Results
1 -
10 of
37Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes, Synthesis of Heterocycles in Contemporary Medicinal Chemistry Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects, Clinical Drug Investigation Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo, Naunyn-Schmiedeberg's Archives of Pharmacology Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice, Naunyn-Schmiedeberg's Archives of Pharmacology Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials, Diabetologia Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes, Clinical Pharmacokinetics Ipragliflozin, a sodiumu2013glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Longu2013Evans Tokushima fatty rats, Journal of Gastroenterology Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials, Acta Diabetologica Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice, Archives of Pharmacal Research